Orofacial Pain Management: An Overview of the Potential Benefits of Palmitoylethanolamide and Other Natural Agents

Pain is the most common symptom that dentists are confronted with, whether acute (pulpitis, acute periodontitis, post-surgery, etc.) or chronic diseases, such as periodontitis, muscle pain, temporomandibular joint (TMJ) disorders, burning mouth syndrome (BMS), oral lichen planus (OLP) and others. The success of therapy depends on the reduction in and management of pain through specific drugs, hence the need to analyze new pain medications with specific activity, which are suitable for long-term use, with a low risk of side effects and interactions with other drugs, and capable of leading to a reduction in orofacial pain. Palmitoylethanolamide (PEA) is a bioactive lipid mediator, which is synthesized in all tissues of the body as a protective pro-homeostatic response to tissue damage and has aroused considerable interest in the dental field due to its anti-inflammatory, analgesic, antimicrobial, antipyretic, antiepileptic, immunomodulatory and neuroprotective activities. It has been observed that PEA could play a role in the management of the pain of orofacial origin, including BMS, OLP, periodontal disease, tongue a la carte and temporomandibular disorders (TMDs), as well as in the treatment of postoperative pain. However, actual clinical data on the use of PEA in the clinical management of patients with orofacial pain are still lacking. Therefore, the main objective of the present study is to provide an overview of orofacial pain in its many manifestations and an updated analysis of the molecular pain-relieving and anti-inflammatory properties of PEA to understand its beneficial effects in the management of patients with orofacial pain, both neuropathic and nociceptive in nature. The aim is also to direct research toward the testing and use of other natural agents that have already been shown to have anti-inflammatory, antioxidant and pain-relieving actions and could offer important support in the treatment of orofacial pain.

[1]  A. Kaye,et al.  Glossopharyngeal Neuralgia: Epidemiology, Risk factors, Pathophysiology, Differential diagnosis, and Treatment Options. , 2022, Health psychology research.

[2]  L. Nahar,et al.  Ethnopharmacology , phytochemistry and biological activities of selected African species of the genus Ficus , 2022 .

[3]  T. Nosratzehi.  Burning mouth syndrome: a review of therapeutic approach , 2021, Journal of complementary & integrative medicine.

[4]  A. Rosén,et al.  Neuropathic orofacial pain: Characterization of different patient groups using the ICOP first edition, in a tertiary level Orofacial Pain Clinic. , 2021, Oral surgery, oral medicine, oral pathology and oral radiology.

[5]  P. Clayton,et al.  Palmitoylethanolamide: A Natural Compound for Health Management , 2021, International journal of molecular sciences.

[6]  P. Caliandro,et al.  Neuropathic Pain in the Elderly , 2021, Diagnostics.

[7]  F. Lobbezoo,et al.  A conceptual model of oro‐facial health with an emphasis on function , 2021, Journal of oral rehabilitation.

[8]  S. Cuzzocrea,et al.  Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain , 2021, International journal of molecular sciences.

[9]  S. Kouam,et al.  Phytochemistry , traditional uses , and pharmacology of the genus Ekebergia ( Meliaceae ) : A review , 2021 .

[10]  Yuling Liu,et al.  The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  A. Jäger,et al.  Analogous modulation of inflammatory responses by the endocannabinoid system in periodontal ligament cells and microglia , 2020, Head & Face Medicine.

[12]  C. Fowler,et al.  Relative Deficiency of Anti-Inflammatory N-Acylethanolamines Compared to Prostaglandins in Oral Lichen Planus , 2020, Biomedicines.

[13]  C. Fowler,et al.  The Basal Pharmacology of Palmitoylethanolamide , 2020, International journal of molecular sciences.

[14]  S. Cuzzocrea,et al.  The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats , 2020, International journal of molecular sciences.

[15]  Yanwei Xing,et al.  Anti-inflammatory and immunomodulatory effects of baicalin in cerebrovascular and neurological disorders , 2020, Brain Research Bulletin.

[16]  Giorgio Cruccu,et al.  Trigeminal Neuralgia. , 2020, The New England journal of medicine.

[17]  Kutty Selva Nandakumar,et al.  Recent Research on Flavonoids and their Biomedical applications. , 2020, Current medicinal chemistry.

[18]  A. Mishra,et al.  Phytochemical, ethanomedicinal and pharmacological applications of escin from Aesculus hippocastanum L. towards future medicine , 2020, Journal of basic and clinical physiology and pharmacology.

[19]  A. Alibrandi,et al.  Effectiveness of a nutraceutical agent in the non-surgical periodontal therapy: a randomized, controlled clinical trial , 2020, Clinical Oral Investigations.

[20]  A. Mamun,et al.  Exploring the Promise of Flavonoids to Combat Neuropathic Pain: From Molecular Mechanisms to Therapeutic Implications , 2020, Frontiers in Neuroscience.

[21]  S. Cuzzocrea,et al.  Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing , 2020, Veterinary sciences.

[22]  H. Flor,et al.  The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. , 2020, Pain.

[23]  M. Moens,et al.  Facial Pain: A Comprehensive Review and Proposal for a Pragmatic Diagnostic Approach , 2020, European Neurology.

[24]  J. Strosznajder,et al.  The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders , 2020, Neurochemical Research.

[25]  Y. Imamura.  International Classification of Orofacial Pain, 1st edition (ICOP) , 2020, Cephalalgia : an international journal of headache.

[26]  Zehra Çalış,et al.  The roles of Flavonoles/Flavonoids in Neurodegeneration and Neuroinflammation. , 2020, Mini reviews in medicinal chemistry.

[27]  J. Chichorro,et al.  Trigeminal Neuralgia: Basic and Clinical Aspects , 2020, Current neuropharmacology.

[28]  T. Renton.  Tooth‐Related Pain or Not? , 2020, Headache.

[29]  A. Akbarzadeh,et al.  The genus Perovskia Kar.: ethnobotany, chemotaxonomy and phytochemistry: a review , 2019, Toxin Reviews.

[30]  A. Akbarzadeh,et al.  Ethnobotany and Phytochemistry of the genus Eremostachys Bunge , 2019, Current Organic Chemistry.

[31]  L. Gallelli.  Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties , 2019, Drug design, development and therapy.

[32]  A. Schneebeli,et al.  Myofascial pain syndrome and trigger points: evaluation and treatment in patients with musculoskeletal pain. , 2019, Current opinion in supportive and palliative care.

[33]  Qiang Sun,et al.  Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology , 2019, The Journal of pharmacy and pharmacology.

[34]  Karolina Bajdak-Rusinek,et al.  The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms , 2019, Inflammation Research.

[35]  L. Ferraro,et al.  Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease , 2019, Front. Pharmacol..

[36]  U. Pesonen,et al.  Neurophysiology and genetics of burning mouth syndrome , 2019, European journal of pain.

[37]  G. Ottaviani,et al.  Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial , 2018, Clinical Oral Investigations.

[38]  Steven D. Bender.  Orofacial Pain: Where We Are and Where We Are Going. , 2018, Dental clinics of North America.

[39]  S. Harte,et al.  Applications of sensory and physiological measurement in oral‐facial dental pain , 2018, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[40]  J. Hietala,et al.  Dopaminergic and serotonergic mechanisms in the modulation of pain: In vivo studies in human brain , 2018, European journal of pharmacology.

[41]  D. Ray,et al.  Molecular Actions of PPARα in Lipid Metabolism and Inflammation. , 2018, Endocrine reviews.

[42]  K. O'Halloran,et al.  Plasma N‐acylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis , 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[43]  Y. F. Liu,et al.  Burning mouth syndrome: a systematic review of treatments. , 2018, Oral diseases.

[44]  A. Toyofuku,et al.  Clinical features of atypical odontalgia; three cases and literature reviews , 2017, BioPsychoSocial Medicine.

[45]  S. E. Kim,et al.  Efficacy of horse chestnut leaf extract ALH-L1005 as a matrix metalloproteinase inhibitor in ligature-induced periodontitis in canine model , 2017, Journal of veterinary science.

[46]  S. Petrosino,et al.  The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations , 2017, British journal of pharmacology.

[47]  R. Banik,et al.  Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. , 2017, European journal of medicinal chemistry.

[48]  C. Fowler,et al.  The anti‐inflammatory compound palmitoylethanolamide inhibits prostaglandin and hydroxyeicosatetraenoic acid production by a macrophage cell line , 2017, Pharmacology research & perspectives.

[49]  E. Esposito,et al.  Immunopharmacology and in fl ammation A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral ef fi cacy compared to their association in a rat paw model of carrageenan-induced in fl ammation , 2016 .

[50]  C. Fowler,et al.  Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy , 2016, British journal of clinical pharmacology.

[51]  D. Harper,et al.  Pain Mechanisms and Centralized Pain in Temporomandibular Disorders , 2016, Journal of dental research.

[52]  S. Soinila,et al.  Peripheral nervous system involvement in primary burning mouth syndrome--results of a pilot study. , 2016, Oral diseases.

[53]  G. Isola,et al.  Anticoagulant therapy in patients undergoing dental interventions: a critical review of the literature and current perspectives. , 2015, Minerva stomatologica.

[54]  R. Capasso,et al.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent , 2015, British journal of pharmacology.

[55]  R. Mensink,et al.  Fatty acid chain length and saturation influences PPARα transcriptional activation and repression in HepG2 cells. , 2014, Molecular nutrition & food research.

[56]  M. Djukic,et al.  Strategies to increase the activity of microglia as efficient protectors of the brain against infections , 2014, Front. Cell. Neurosci..

[57]  A. Padovani,et al.  Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis. , 2014, Histology and histopathology.

[58]  L. Facci,et al.  Mast cells, glia and neuroinflammation: partners in crime? , 2014, Immunology.

[59]  R. Witkamp,et al.  Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold , 2013, International journal of inflammation.

[60]  V. Marzo,et al.  Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy , 2013, Neuropharmacology.

[61]  T. Uyama,et al.  Metabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways , 2013, The FEBS journal.

[62]  A. Colombo,et al.  Send Orders of Reprints at Reprints@benthamscience.net Non-neuronal Cell Modulation Relieves Neuropathic Pain: Efficacy of the Endogenous Lipid Palmitoylethanolamide , 2022 .

[63]  S. Cuzzocrea,et al.  Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. , 2013, CNS & neurological disorders drug targets.

[64]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[65]  R. Meli,et al.  Palmitoylethanolamide Protects Against the Amyloid-β25-35-Induced Learning and Memory Impairment in Mice, an Experimental Model of Alzheimer Disease , 2012, Neuropsychopharmacology.

[66]  T. Hanakawa.  Neural mechanisms underlying deafferentation pain: a hypothesis from a neuroimaging perspective , 2012, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[67]  S. Jääskeläinen.  Pathophysiology of primary burning mouth syndrome , 2012, Clinical Neurophysiology.

[68]  M. R. Gatto,et al.  Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. , 2012, Journal of orofacial pain.

[69]  P. Puukka,et al.  Pain and pain behavior in burning mouth syndrome: a pain diary study. , 2012, Journal of orofacial pain.

[70]  D. Nixdorf,et al.  Persistent Dento-Alveolar Pain Disorder (PDAP): Working towards a Better Understanding , 2011, Reviews in pain.

[71]  A. Teixeira,et al.  The impact of burning mouth syndrome on health-related quality of life , 2011, Health and quality of life outcomes.

[72]  F. Silvestre-Donat,et al.  Etiology of burning mouth syndrome: a review and update. , 2011, Medicina oral, patologia oral y cirugia bucal.

[73]  T. Renton.  Dental (Odontogenic) Pain , 2011, Reviews in pain.

[74]  C. Woolf.  Central sensitization: Implications for the diagnosis and treatment of pain , 2011, PAIN.

[75]  T. Uyama,et al.  Enzymological studies on the biosynthesis of N-acylethanolamines. , 2010, Biochimica et biophysica acta.

[76]  D. Becker.  Pain management: Part 1: Managing acute and postoperative dental pain. , 2010, Anesthesia progress.

[77]  C. Woolf,et al.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity. , 2009, The journal of pain : official journal of the American Pain Society.

[78]  B. Costa,et al.  The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors , 2008, PAIN.

[79]  C. Guarneri,et al.  Contribution of neuroinflammation in burning mouth syndrome: indications from benzodiazepine use , 2008, Dermatologic therapy.

[80]  R. Benoliel,et al.  Neuropathic orofacial pain. , 2008, Oral and maxillofacial surgery clinics of North America.

[81]  R. Zain,et al.  Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. , 2007, Journal of oral science.

[82]  P. Abbott,et al.  An overview of the dental pulp: its functions and responses to injury. , 2007, Australian dental journal.

[83]  P. Anand,et al.  Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score , 2007, Journal of Clinical Neuroscience.

[84]  C. J. Spencer,et al.  Neuropathic orofacial pain: proposed mechanisms, diagnosis, and treatment considerations. , 2007, Dental clinics of North America.

[85]  I. Siafaka,et al.  Therapeutic Management of Chronic Neuropathic Pain , 2006, Annals of the New York Academy of Sciences.

[86]  C. Fowler,et al.  Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors , 2005, British journal of pharmacology.

[87]  J. Tajti,et al.  Evidence-based pharmacological treatment of neuropathic pain syndromes , 2005, Journal of Neural Transmission.

[88]  R. Levi‐montalcini,et al.  A proposed autacoid mechanism controlling mastocyte behaviour , 2005, Agents and Actions.

[89]  A. Scala,et al.  Update on burning mouth syndrome: overview and patient management. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[90]  Kjell Någren,et al.  Striatal dopamine D1 and D2 receptors in burning mouth syndrome , 2003, Pain.

[91]  S. Jääskeläinen,et al.  Sensory dysfunction in burning mouth syndrome , 2002, PAIN.

[92]  K. Kurita,et al.  Pain threshold and pain recovery after experimental stimulation in patients with burning mouth syndrome , 2002, Psychiatry and clinical neurosciences.

[93]  F. Calabrò,et al.  Patologia dell'articolazione temporo-mandibolare , 2000 .

[94]  C. Woolf,et al.  Neuropathic pain: aetiology, symptoms, mechanisms, and management , 1999, The Lancet.

[95]  M. Närhi,et al.  Dental injury models: experimental tools for understanding neuroinflammatory interactions and polymodal nociceptor functions. , 1999, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[96]  P. Low,et al.  Symptomatic treatment of painful neuropathy. , 1998, JAMA.

[97]  S. Jääskeläinen,et al.  Abnormalities of the blink reflex in burning mouth syndrome , 1997, Pain.

[98]  R. Leimola-Virtanen,et al.  Effect of hormone replacement therapy on salivary flow rate, buffer effect and ph in perimenopausal and postmenopausal , 1996 .

[99]  P. Svensson,et al.  General health factors and denture function in patients with burning mouth syndrome and matched control subjects. , 1995, Journal of oral rehabilitation.

[100]  H. Burger,et al.  Oral discomfort at menopause. , 1989, Oral surgery, oral medicine, and oral pathology.

[101]  L. Olgart.  The Role of Local Factors in Dentin and Pulp in Intradental Pain Mechanisms , 1985, Journal of dental research.

[102]  J. Stevens,et al.  Glossopharyngeal (vagoglossopharyngeal) neuralgia: a study of 217 cases. , 1981, Archives of neurology.

[103]  R. Kroening,et al.  Recognition and treatment of patients with chronic orofacial pain. , 1979, Journal of the American Dental Association.